![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 27, 2023 10:43:16 AM
Potential oral therapy in Phase 2b clinical trial with results likely this year
https://alsnewstoday.com/news/primec-boosts-survival-als-patient-derived-motor-neurons/#:~:text=PrimeC%20combines%20the%20antibiotic%20ciprofloxacin,NEALS)%20annual%20meeting%20in%20Florida.
PrimeC, NeuroSense Therapeutics‘ investigational, fixed-dose combination therapy for amyotrophic lateral sclerosis (ALS), significantly boosted the survival of patient-derived motor neurons to levels similar to healthy controls in a lab study.
The independent study was led by Justin Ichida, PhD, a professor of stem cell biology and regenerative medicine at the University of Southern California (USC).
“Dr. Ichida has been described as being beyond the cutting edge in his field and we are honored that he and his lab chose to evaluate PrimeC in this non-sponsored study,” Alon Ben Noon, founder and CEO of NeuroSense, said in a company press release.
PrimeC combines the antibiotic ciprofloxacin with anti-inflammatory celecoxib
Findings were presented by Shiran Zimri, PhD, NeuroSense’s vice-president of research and development, at the recent Northeast Amyotrophic Lateral Sclerosis (NEALS) annual meeting in Florida.
“These results further bolster our confidence that PrimeC may offer a much-needed therapy for this debilitating disease,” Noon said.
PrimeC is an oral, fixed-dose combination of two approved compounds with well-established safety profiles: the antibiotic ciprofloxacin and the anti-inflammatory celecoxib.
Together, the medications are expected to prevent ALS progression by targeting inflammation and other mechanisms that damage motor neurons, the nerve cells in the brain and spinal cord that coordinate movement by sending commands to muscle cells.
Ichida and his team at USC’s Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research examined the efficacy of PrimeC in patient-derived motor neurons.
These cells were generated from blood cells using a kind of cellular programming. First, the scientists collected blood cells from ALS patients and healthy people. Then, through a series of biochemical manipulations, the blood cells were reprogrammed into induced pluripotent stem cells, or iPSCs, which are lab-made stem cells able to grow into other types of cells.
Because the iPSCs retain the genetic code of the person that the blood cells were collected from, they enable the creation of nerve cells that recapitulate the same features of diseased motor neurons. iPCS also provide an almost unlimited source of patient-derived motor neurons, which can be used for large screenings of potential therapies.
“At our lab, we screen thousands of compounds in search of one that may be effective in ALS, and we were very impressed by the data resulting from our iPCS in vitro study of PrimeC,” Ichida said. “We chose to evaluate PrimeC based on the growing body of clinical, pre-clinical, and biomarker data on its efficacy in ALS.”
PrimeC protected motor neurons more effectively than its components alone
In a previous study, Ichida found PrimeC to be among the best at improving motor neuron survival in a list that included multiple approved and experimental ALS therapies, NeuroSense reported, adding that PrimeC outperformed Relyvrio (sodium phenylbutyrate and taurursodiol) and Radicava (edaravone) in that study’s model.
In the current study, researchers compared survival rates of ALS motor neurons with PrimeC versus each of its components. They also tested each of those treatments against motor neurons derived from healthy individuals.
Data showed that, while both ciprofloxacin and celecoxib led to significantly better survival rates than no treatment, the combination therapy was better than either drug alone at improving cell survival.
Notably, ALS motor neurons treated with PrimeC had survival rates similar to those seen in healthy motor neurons, NeuroSense reported.
“These findings present a new opportunity to potentially screen super responder patients using iPSCs, a non-invasive method which only requires a blood draw from the patient. Using this screening model may result in higher efficacy in people living with ALS who are most likely to benefit from PrimeC,” Zimri said.
In a Phase 2a clinical trial (NCT04165850) that concluded in 2021, an early formulation of PrimeC showed a potential to safely slow overall disease progression and lung function decline compared with an historical group of patients.
A new, extended-release formulation of PrimeC is being investigated in a Phase 2b clinical trial, called PARADIGM (NCT05357950). There, 69 adults were randomly assigned to the experimental medicine or a placebo, given twice daily for six months alongside standard ALS medications. Top-line trial findings are expected in the coming months.
Recent NRSN News
- NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results • PR Newswire (US) • 06/24/2024 01:00:00 PM
- NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal • PR Newswire (US) • 06/21/2024 08:30:00 PM
- NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit • PR Newswire (US) • 05/20/2024 01:00:00 PM
- NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning • PR Newswire (US) • 05/14/2024 01:05:00 PM
- NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients • PR Newswire (US) • 05/07/2024 12:45:00 PM
- NeuroSense Announces First Quarter 2024 Business Update • PR Newswire (US) • 05/02/2024 01:19:00 PM
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease • PR Newswire (US) • 04/22/2024 12:30:00 PM
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 • PR Newswire (US) • 04/12/2024 12:30:00 PM
- NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 04/10/2024 11:16:00 PM
- NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics • PR Newswire (US) • 04/09/2024 12:30:00 PM
- NeuroSense Announces Year End 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/05/2024 01:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 01:25:59 PM
- NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial • PR Newswire (US) • 02/21/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 06:20:37 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 03:14:40 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 02:38:16 PM
- NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule • PR Newswire (US) • 02/07/2024 02:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:49:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:48:26 PM
- NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts • PR Newswire (US) • 01/09/2024 01:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/27/2023 10:03:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 10:01:06 PM
- NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement • PR Newswire (US) • 12/27/2023 10:00:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM